エネルギーと環境 · 2026/4/301 分で読めます
In the Matter of SHINE Technologies, LLC; SHINE Medical Isotope Production Facility; Direct and Indirect Transfers of License
ローカル自動翻訳 · 情報源の原言語
概要
The U.S. Nuclear Regulatory Commission (NRC) is issuing an order approving the license transfer application filed by SHINE Technologies, LLC, dated February 4, 2026, as supplemented on April 13, 2026. Specifically, the order approves the direct transfer of Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility from SHINE Technologies, LLC to SHINE Chrysalis, LLC and a conforming license amendment. The order also approves the indirect transfer of control of the construction permit as a result of the establishment of SHINE Chrysalis Holdings, LLC as the direct parent company of SHINE Chrysalis, LLC. SHINE Chrysalis Holdings, LLC is a wholly owned subsidiary of Illuminated Holdings, Inc., the current parent company of SHINE Technologies, LLC.